Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Succinate dehydrogenase germline mutation carriers: before tumours develop.

Created on 21 Aug 2026

Authors

Eugenie S Lim, Jean-Pierre Bayley, Anne-Paule Gimenez-Roqueplo, Roderick J Clifton-Bligh, Susan Richter

Published in

Endocrine-related cancer. Aug 21, 2026. Epub Aug 21, 2026.

Abstract

Succinate dehydrogenase (SDH) is an enzyme complex that plays a major role in cellular metabolism, as it sits at the interface between carbon metabolism in the Krebs cycle and oxidative phosphorylation for energy production. The precursor and product of the enzymatic reaction, succinate and fumarate, respectively, are regulators of various cellular and biological processes such as epigenetic status, hypoxia responses and angiogenesis, metabolic reprogramming, tumorigenesis, and immune responses. Succinate is considered an oncometabolite, and SDHx genes are tumour suppressor genes. Carriers of germline pathogenic variants (PV) in one of the SDHx genes (SDHA, SDHB, SDHC, SDHD, SDHAF2) carry a life-long risk of developing tumours, predominantly paragangliomas and phaeochromocytomas (PPGL). Research has focused mainly on the disease state in which, in accordance with the Knudson two-hit model, the second allele is inactivated in tumour cells; the biological consequences of which are massive intracellular accumulation of succinate and/or reactive oxygen species (ROS), which in turns leads to tumourigenesis. Little is known about the haplo-insufficient state, in which the wild-type SDHx copy at least partially sustains SDH function and keeps intracellular succinate and ROS levels in ranges that are, if not normal, then at least non-tumourigenic. This review will consolidate the literature regarding genotype differences between SDHx PV carriers, the phenotype of non-tumoral cells in healthy individuals, and the role of environmental factors in influencing tumour development, potentially via tipping succinate (or ROS) levels above a tumourigenic threshold.

PMID:
42626917
Bibliographic data and abstract were imported from PubMed on 21 Aug 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 10
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement